The billionaire investor Carl C. Icahn said yesterday that he had reached an agreement with the biotechnology firm ImClone Systems to avoid a possible proxy contest.
In a filing with the Securities and Exchange Commission, Mr. Icahn said ImClone’s board offered to put him and three of his recommended candidates on the management slate of director nominees for the 2006 annual stockholders’ meeting, which is scheduled for Sept. 20.
Thursday, August 24, 2006
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment